Skip to main content
SpringerLink
Log in

Antiemetics in cancer chemotherapy: historical perspective and current state of the art

  • Review Article
  • Published:
Supportive Care in Cancer Aims and scope Submit manuscript

Abstract

Chemotherapy-related nausea and vomiting can today be controlled with available antiemetics in a high percentage of patients but emesis remains a problem for some patients, with certain drugs and with repeated cycles of chemotherapy. The fundamental steps of clinical research in antiemetics towards the improvement of the control of nausea and vomiting with new drugs or combinations are presented. Special emphasis is given to cisplatin-induced nausea and vomiting because of the frequency and relevance of this phenomenon. The use of high-dose metoclopramide, its combination with steroids, and later the addition of lorazepam or diphenhydramine represented the evolving standard of the 1980s, with the level of complete protection from vomiting improving from 30%–40% to 60%–70% with the three-drug combination. The introduction of new agents such as the 5-hydroxytryptamine 3 (5-HT3) receptor antagonists has recently offered new possibilities because of their activity and lack of toxicity. In particular, the combination of ondansetron plus dexamethasone is today the most efficacious and least toxic antiemetic treatment for prevention of emesis in patients treated with a single high dose or low repeated doses of cisplatin. A comparison of different 5-HT3 antagonists, always in combination with steroids, is now considered necessary. For patients treated with moderately emetogenic chemotherapy the use of steroids can still be considered the standard treatment. In this setting, the role of 5-HT3 receptor antagonists, alone or in combination with steroids, has to be better defined through large, well-planned clinical trials, which should have a cost-effectiveness analysis as one of their goals.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Allan SG, Cornbleet MA, Warrington PS, et al (1984) Dexamethasone and high-dose metoclopramide: efficacy in controlling cisplatin induced nausea and vomiting. Br Med J 13:235–237

    Google Scholar 

  2. Andrews PLR, Rapeport WG, Sanger GJ (1988) Neuropharmacology of emesis induced by anti-cancer therapy. Trends Pharmacol Sci 9:334–341

    Google Scholar 

  3. Ballard HS, Bottino G, Bottino J (1992) Ondansetron and chest pain (letter). Lancet 340:1107

    Google Scholar 

  4. Basurto C, Roila F, Bracarda S, et al (1988) A double-blind trial comparing antiemetic efficacy and toxicity of metoclopramide versus methylprednisolone versus domperidone in patients receiving doxorubicin chemotherapy alone or in coimbination with other antiblastic agents. Am J Clin Oncol 11:594–596

    Google Scholar 

  5. Basurto C, Roila F, Del Favero A, et al (1988) A prospective randomized double-blind crossover study comparing the antiemetic activity of alizapride and metoclopramide in patients receiving cisplatin chemotherapy. Cancer Invest 6:475–479

    Google Scholar 

  6. Beck TM, Madajewicz S, Navari RM, et al (1992) A double-blind, stratified, randomized comparison of intravenous (iv) ondansetron administered as a multiple dose regimen versus two single dose regimens in the prevention of cisplatin-induced nausea and vomiting. Proc Am Soc Clin Oncol 11:378

    Google Scholar 

  7. Bécouarn Y, Bui NB, David M, et al (1986) Improved control of cis-platin-induced emesis with a combination of high doses of methylprednisolone and metoclopramide: a single-blind randomized trial. Eur J Cancer Oncol 22:1421–1424

    Google Scholar 

  8. Benrubi GI, Norvell M, Nuss RC, et al (1985) The use of methylprednisolone and metoclopramide in control of emesis in patients receiving cisplatin. Gynecol Oncol 21:306–313

    Google Scholar 

  9. Blackwell CP, Harding SM (1989) The clinical pharmacology of ondasetron. Eur J Cancer Clin Oncol 25:521–524

    Google Scholar 

  10. Bonneterre J, Chevallier B, Metz R, et al (1990) A randomized doubleblind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil and doxorubicin or epirubicin chemotherapy. J Clin Oncol 8:1063–1069

    Google Scholar 

  11. Burton G, Huang A, Lazarus H, et al (1990) A double-blind randomized comparison of three doses of i.v. ondansetron for prevention of emesis induced by multi-day cisplatin therapy. Proc Am Soc Clin Oncol 9:328

    Google Scholar 

  12. Castle WM, Cunningham K, Kanarek BB (1992) Ondansetron is not associated with vascular adverse events, thrombocytopenia or renal failure (letter). Ann Oncol 3:773–774

    Google Scholar 

  13. Chevallier B, on behalf of the Granisetron Study Group (1990) Efficacy and safety of granisetron compared with high-dose metoclopramide plus dexamethasone in patients receiving high-dose cisplatin in a single-blind study. Eur J Cancer 26 [Suppl 1]:33–36

    Google Scholar 

  14. Chiara S, Scarfi P, Campora E, et al (1984) Low-dose metoclopramide versus methylprednisolone in controlling chemotherapy-induced nausea and vomiting. Chemioterapia 3:333–336

    Google Scholar 

  15. Chiara S, Campora E, Lionetto R, et al (1987) Methylprednisolone for the control of CMF-induced emesis. Am J Clin Oncol 10:264–267

    Google Scholar 

  16. Coates A, Abraham S, Kaye SB, et al (1983) On the receiving end—patient perception of the side-effects of cancer chemo-therapy. Eur J Cancer Clin Oncol 19:203–208

    Google Scholar 

  17. Coates AS, Childs A, Cox K, et al (1992) Severe vascular adverse effects with thrombocytopenia and renal failure following emetogenic chemotherapy and ondansetron. Ann Oncol 3:719–722

    Google Scholar 

  18. Cognetti F, Pinnarò P, Carlini P, et al (1984) Randomized open crossover trial between metoclopramide (MCP) and dexamethasone (DXM) for the prevention of cisplatin induced nausea and vomiting. Eur J Cancer Clin Oncol 20:183–187

    Google Scholar 

  19. Cunningham D, Turner A, Hawthorn J, et al (1989) Ondansetron with and without dexamethasone to treat chemotherapy-induced emesis. Lancet I:1323

    Google Scholar 

  20. Dana BW, Everts EC, Dickinson D (1985) Dexamethasone vs placebo for cisplatin induced emesis. A randomized cross-over trial. Am J Clin Oncol 8:426–428

    Google Scholar 

  21. David M, Durand M, Chauvergne J, et al (1984) Cyclophosphamide, methotrexate, and 5-FU (CMF)-induced nausea and vomiting: a controlled study with high-dose metoclopramide. Cancer Treat Rep 68:921–922

    Google Scholar 

  22. De Haan LD, De Mulder PHM, Beex LVAM, et al (1988) The efficacy of GR38032F an antagonist of 5-hydroxytryptamine-3 (5-HT3) in the prophylaxis of cisplatin (CDDP)-induced nausea and vomiting. Eur J Cancer Clin Oncol 24:1383–1384

    Google Scholar 

  23. De Mulder PHM, Seynaeve C, Vermorken JAB, et al (1990) Ondansetron compared with high-dose metoclopramide in prophylaxis of acute and delayed cisplatin-induced nausea and vomiting. A multicenter, randomized, double-blind, crossover study. Ann Intern Med 113:8334–8340

    Google Scholar 

  24. Dicato M (1991) Oral treatment with ondansetron in an outpatient setting. Eur J Cancer 27 [Suppl 1]:518–519

    Google Scholar 

  25. Diehl V, on behalf of the Granisetron Study Group (1992) Fractionated chemotherapy—granisetron or conventional antiemetics? Eur J Cancer 28A [Suppl 1]:21–28

    Google Scholar 

  26. Dobrow RB, Coppock MA, Hosenpud JR (1991) Extrapyramidal reaction caused by ondansetron. J Clin Oncol 9:1921

    Google Scholar 

  27. D'Olimpo JT, Camacho F, Chandra P, et al (1985) Antiemetic efficacy of high-dose dexamethasone vs placebo in patients receiving cisplatin-based chemotherapy: a randomized double blind controlled clinical trial. J Clin Oncol 3:1133–1135

    Google Scholar 

  28. Edge SB, et al (1987) High-dose oral and intravenous metoclopramide in doxorubicin/cyclophosphamide-induced emesis. Am J Clin Oncol 10:257–263

    Google Scholar 

  29. Einhorn LH, Nagy C, Werner K, et al (1990) Ondansetron: a new antiemetic for patients receiving cisplatin chemotherapy. J Clin Oncol 8:731–735

    Google Scholar 

  30. Fetting JH, Grochow LB, Folstein MF, et al (1982) The course of nausea and vomiting after high-dose cyclophosphamide. Cancer Treat Rep 66:1487–1493

    Google Scholar 

  31. Fetting JH, McCarthy LE, Borison HL, et al (1982) Vomiting induced by cyclophosphamide and phosphoramide mustard in cats. Cancer Treat Rep 66:1625–1629

    Google Scholar 

  32. Fraschini G, Ciociola A, Esparaza L, et al (1991) Evaluation of three oral dosages of ondansetron in the prevention of nausea and emesis associated with cyclophosphamide-doxorubicin chemotherapy. J Clin Oncol 9:1268–1274

    Google Scholar 

  33. Frustaci S, Grattoni E, Tumolo S, et al (1986) Randomized cross-over antiemetic study in cisplatin treated patients. Comparison between high-dose IV metoclopramide and high-dose IV dexamethasone. Cancer Chemother Pharmacol 17:75–79

    Google Scholar 

  34. Gralla RJ (1992) Serotonin antagonist antiemetics: progress and concerns (editorial). Ann Oncol 3:677–678

    Google Scholar 

  35. Gralla RJ, Braun TJ, Squillante A, et al (1981) Metoclopramide: initial clinical studies of high dosage regimen in cisplatin-induced emesis. In: Poster D (ed) The treatment of nausea and vomiting induced by cancer chemotherapy. Masson, New York, pp 167–176

    Google Scholar 

  36. Gralla RJ, Itri LM, Piski SE, et al (1981) Antiemetic efficacy of high-dose metoclopramide: randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. N Engl J Med 305:905–909

    Google Scholar 

  37. Grunberg SM, Stevenson LL, Russell CA, et al (1989) GR38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705

    Google Scholar 

  38. Hainsworth J, Harvey W, Pendergrass K, et al (1991) A single-blind comparison of intravenous ondansetron, a selective serotonin antagonist, with intravenous metoclopramide in the prevention of nausea and vomiting associated with high-dose cisplatin chemotherapy. J Clin Oncol 9:721–728

    Google Scholar 

  39. Hainsworth JD, Omura GA, Khoiasteh A, et al (1991) Ondansetron (GR38032F): a novel antiemetic effective in patients receiving a multiple-day regimen of cisplatin chemotherapy. Am J Clin Oncol 14:336–340

    Google Scholar 

  40. Hawthorne J, Cunningham D (1990) Dexamethasone can potentiate the anti-emetic action of a 5HT3 receptor antagonist on cyclophosphamide induced vomiting in the ferret. Br J Cancer 61:56–60

    Google Scholar 

  41. Hesketh PJ, Murphy WK, Lester EP, et al (1989) GR38032F (GR-C507/75): a novel compound effective in the prevention of acute cisplatin-induced emesis. J Clin Oncol 7:700–705

    Google Scholar 

  42. Hesketh PJ, Twaddell T, Finn A (1990) A possible role for cisplatin in the transient hepatic enzyme elevations noted after ondansetron administration. Proc Am Soc Clin Oncol 9:323

    Google Scholar 

  43. Higgins GA, Kilpatrick GJ, Bruce KT, et al (1989) 5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol 97:247–255

    Google Scholar 

  44. Homesley HD, Gainey JM, Jobson VN, et al (1982) Double-blind placebo-controlled study of metoclopramide in cisplatin-induced emesis. N Engl J Med 307:250–251

    Google Scholar 

  45. Italian Group for Antiemetic Research (1992) Ondansetron+dexamethasone vs metoclopramide+dexamethasone+diphenhydramine in prevention of cisplatin-induced emesis. Lancet 340:96–99

    Google Scholar 

  46. Jones AL, Hill AS, Soukop M, et al (1991) Comparison of ondansetron vs dexamethasone in the prophylaxis of emesis induced by moderately emetogenic chemotherapy. Lancet 338:483–487

    Google Scholar 

  47. Jordan NS, Schauer PK, Schauer A, et al (1985) The effect of administration rate of cisplatin induced emesis. J Clin Oncol 3:559–561

    Google Scholar 

  48. Joss RA, Galeazzi RL, Bischoff AK, et al (1986) The antiemetic activity of high-dose alizapride and high-dose metoclopramide in patients receiving cancer chemotherapy: a prospective, randomized, double-blind trial. Clin Pharmacol Ther 39:619–624

    Google Scholar 

  49. Kaasa S, Kvalov S, Dicato MA, et al (1990) A comparison of ondansetron with metoclopramide in the prophylaxis of chemotherapy-induced nausea and vomiting: a randomized, doubleblind study. Eur J Cancer 26:311–314

    Google Scholar 

  50. Kris MG, Tyson LB, Gralla RJ, et al (1983) Extrapyramidal reactions with high-dose metoclopramide. N Engl J Med 309:433

    Google Scholar 

  51. Kris MG, Gralla RJ, Tyson LB, et al (1985) Improved control of cisplatin induced emesis with high dose metoclopramide and with combinations of metoclopramide, dexamethasone and diphenhydramine. Results of consecutive trials in 255 patients. Cancer 55:527–534

    Google Scholar 

  52. Kris MG, Gralla RJ, Clark RA, et al (1987) Antiemetic control and prevention of side efects of anticancer therapy with lorezapam or diphenhydramine when used in combination with metoclopramide plus dexamethasone. A double-blind, randomized trial. Cancer 60:2816–2822

    Google Scholar 

  53. Kris MG, Gralla RJ, Clark RA, et al (1988) Dose-ranging evaluation of the serotonin antagonist GR-C507/75 (GR38032F) when used as an antiemetic in patients receiving anticancer chemotherapy. J Clin Oncol 6:659–662

    Google Scholar 

  54. Kris MG, Gralla RJ, Clark RA, et al (1989) Phase II trials of the serotonin antagonist GR38032F for the control of vomiting caused by cisplatin. J Natl Cancer Inst 81:42–46

    Google Scholar 

  55. Lane M, Grunberg SM, Lester EP, et al (1990) A double-blind comparison of three dose levels of i.v. ondansetron in the prevention of cisplatin-induced nausea and vomiting. Proc Soc Clin Oncol 9:329

    Google Scholar 

  56. Markman M, Sheidler V, Ettinger DS, et al (1984) Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy. N Engl J Med 311:549–552

    Google Scholar 

  57. Marschner NW, Adler M, Nagel GA, et al (1991) Double-blind randomized trial of the antiemetic efficacy and safety of ondansetron and metoclopramide in advanced breast cancer patients treated with epirubicin and cyclophosphamide. Eur J Cancer 27:1137–1140

    Google Scholar 

  58. Marty M, Droz JP, Pouillart P, et al (1989) GR38032F, a 5HT3 receptor antagonist, in the prophylaxis of acute cisplatin-induced nausea and vomiting. Cancer Chemother Pharmacol 23:389–391

    Google Scholar 

  59. Marty M, on behalf of the Granisetron Study Group (1990) A comparative study of the use of granisetron, a selective 5-HT3 antagonist, versus a standard anti-emetic regimen of chloropromazine plus dexamethasone in the treatment of cytostatic-induced emesis. Eur J Cancer 26 [Suppl 1]: 28–32

    Google Scholar 

  60. Marty M, d'Allens H, et le Groupe Multicentrique Francais (1990) Etude randomisée en double-insu comparant l'efficacité de l'ondansetron selon deux modes d'administration: injection unique et perfusion continue. Cah Cancer 2:541–546

    Google Scholar 

  61. Marty M, Pouillart P, School S, et al (1990) Comparison of the 5-hydroxytryptamine 3 (serotonin) antagonist ondansetron (GR38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 322:816–821

    Google Scholar 

  62. Mellink WA, Blinihim GH, Van Deyk WA (1984) Amitriptyline plus fluphenazine to prevent chemotherapy-induced emesis in cancer patients: a double-blind randomized cross-over study. Eur J Cancer Clin Oncol 20:1147–1150

    Google Scholar 

  63. Metz CA, Freedman RS, Magrina JF (1987) Methylprednisolone in cisplatin induced nausea and emesis: a placebo-controlled trial. Gynecol Oncol 27:84–89

    Google Scholar 

  64. Morran C, Smith DC, Anderson DA, et al (1979) Incidence of nausea and vomiting with cytotoxic chemotherapy. A prospective randomized trial of antiemetics. Br Med J 1:1323–1324

    Google Scholar 

  65. Peroutka SJ, Snyder SH (1982) Antiemetics: neurotransmitter receptor binding predicts therapeutic actions. Lancet I:658–659

    Google Scholar 

  66. Pollera CF, Nardi M, Marolla P, et al (1989) Effective control of CMF-related emesis with high-dose dexamethasone: results of a double-blind crossover trial with metoclopramide and placebo. Am J Clin Oncol 12:524–529

    Google Scholar 

  67. Roila F, Tonato M, Basurto C, et al (1985) Antiemetic activity of two different high doses of metoclopramide in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. Cancer Treat Rep 69:1353–1357

    Google Scholar 

  68. Roila F, Tonato M, Basurto C, et al (1987) Antiemetic activity of high doses of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients: a randomized double-blind trial of the Italian Oncology Group for Clinical Research. J Clin Oncol 5:141–149

    Google Scholar 

  69. Roila F, Tonato M, Basurto C, et al (1987) Double-blind controlled trial of the antiemetic efficacy and toxicity of methylprednisolone (MP), metoclopramide (MTC) and domperidone (DMP) in breast cancer patients treated with iv CMF. Eur J Cancer Clin Oncol 23:615–617

    Google Scholar 

  70. Roila F, Basurto C, Minotti V, et al (1988) Methylprednisolone versus metoclopramide for prevention of nausea and vomiting in breast cancer patients treated with intravenous cyclophosphamide, methotrexate, 5-fluorouracil: a double-blind randomized study. Oncology 45:346–349

    Google Scholar 

  71. Roila F, Tonato M, Basurto C, et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high-dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and diphenhydramine: a study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693–1700

    Google Scholar 

  72. Roila F, Bracarda S, Tonato M, et al (1990) Ondansetron (GR38032F) in the prophylaxis of acute and delayed cisplatin0induced emesis. Clin Oncol 2:268–272

    Google Scholar 

  73. Roila F, Basurto C, Bracarda S, et al (1991) Double-blind crossover trial of single vs divided dose of metoclopramide in a combined regimen for treatment of cisplatin-induced emesis. Eur J Cancer 27:119–121

    Google Scholar 

  74. Roila F, Tonato M, Cognetti F, et al (1991) Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:675–678

    Google Scholar 

  75. Roila F, Tonato M, Del Favero A (1991) Publication of unethical studies on the treatment of chemotherapy-induced emesis. J Clin Oncol 9:891

    Google Scholar 

  76. Saller R, Hellenbrecht D (1985) Comparison of the antiemetic efficacy of two high-dose benzamides, metoclopramide and alizapride, against antiemetic-induced emesis. Cancer Treat Rep 69:1301–1303

    Google Scholar 

  77. Schallier D, Van Belle S, De Greve J, et al (1985) Methylprednisolone as an antiemetic drug. A randomized double blind study. Cancer Chemother Pharmacol 14:235–237

    Google Scholar 

  78. Seynaeve C, Schuller J, Buser K, et al (1992) Comparison of the anti-emetic efficacy of different doses of ondansetron, given as either a continuous infusion or a single intravenous dose, in acute cisplatin-induced emesis. A multicentre, double-blind, randomized, parallel group study. Br J Cancer 66:192–197

    Google Scholar 

  79. Shinkai T, Saii N, Eguchi K, et al (1986) Antiemetic efficacy of high-dose intravenous metoclopramide and dexamethasone in patients receiving cisplatin-based chemotherapy: a randomized controlled trial. Jpn J Clin Oncol 16:279–287

    Google Scholar 

  80. Sledge GW, Einhorn LH, Nagy C, et al (1990) Randomized trial of ondansetron and metoclopramide as antiemetic therapy for cisplatin-based chemotherapy. Proc Am Soc Clin Oncol 9:323

    Google Scholar 

  81. Smaldone L, Al-Sarraf M, Aapro M, et al (1991) Randomized double-blind crossover comparison of batanopride (BMY-25801) and metoclopramide (MTC) in patients receiving cisplatinbased chemotherapy. Proc Am Soc Clin Oncol 10:342

    Google Scholar 

  82. Smaldone L, Murphy R, Gralla R, et al (1991) Antiemetic activity of batanopride (BMY-25801) in patients receiving cisplatin: a randomized double-blind parallel comparison of two doses. Proc Am Soc Clin Oncol 10:326

    Google Scholar 

  83. Smith DB, Newlands ES, Spruyt OW, et al (1990) Ondansetron (GR38032F) plus dexamethasone: effective anti-emetic prophylaxis for patients receiving cytotoxic chemotherapy. Br J Cancer 61:323–324

    Google Scholar 

  84. Smith DB, Newlands ES, Rustin GJS, et al (1991) Comparison of ondansetron and ondansetron plus dexamethasone as antiemetic prophylaxis during cisplatin-containing chemotherapy. Lancet 338:487–490

    Google Scholar 

  85. Smith IE, on behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving moderately emetogenic cytostatic chemotherapy. Eur J Cancer 26 [Suppl 1]:19–23

    Google Scholar 

  86. Smith RH (1989) Safety of ondansetron. Eur J Cancer Clin Oncol 25:547–550

    Google Scholar 

  87. Smyth JF, Coleman RE, Nicolson M, et al (1991) Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? Br Med J 303:1423–1426

    Google Scholar 

  88. Sorbe B, Frankendal B, Glimelius B, et al (1990) A multicentre randomized study comparing the anti-emetic effects of the 5-HT3 antagonist IC5 205-930 with a metoclopramide-containing anti-emetic cocktail in patients receiving cisplatin chemotherapy. Ann Oncol 1 [Suppl]:113

    Google Scholar 

  89. Soukop M, on behalf of the Granisetron Study Group (1990) A comparison of two dose levels of granisetron in patients receiving high-dose cisplatin. Eur J Cancer 26 [Suppl 1]:15–19

    Google Scholar 

  90. Strum SB, McDermed JE, Liponi DF (1985) High-dose intravenous metoclopramide vs combination high-dose metoclopramide and intravenous dexamethasone in preventing cisplatin-induced nausea and emesis: a single-blind cross-over comparison of antiemetic efficacy. J Clin Oncol 3:245–251

    Google Scholar 

  91. Tonato M, Roila F, Del Favero A (1991) Methodology of antiemetic trials: a review. Ann Oncol 2:107–114

    Google Scholar 

  92. Tyers MD, Bunce KT, Humphrey PPA (1989) Pharmacological and antiemetic properties of ondansetron. Eur J Cancer Clin Oncol 25 [Suppl 1]:15–19

    Google Scholar 

  93. Venner P, for the clinical trials group of National Cancer Institute of Canada (1990) Granisetron for high dose cisplatin induced emesis: a randomized double blind study. Proc Am Soc Clin Oncol 9:320

    Google Scholar 

  94. Warr D, Willan A, Fine S, et al (1991) Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis. J Natl Cancer Inst 83:1169–1173

    Google Scholar 

  95. Weissbach L, for the Multi-day Cisplatin Emesis Study Group (1991) Ondansetron. Lancet 338:753

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Medical Oncology, Policlinico, I-06100, Perugia, Italy

    M. Tonato & F. Roila

  2. Institute of Internal Medicine I, University of Perugia, I-06100, Perugia, Italy

    A. Del Favero

  3. Institute of Statistics, University of Perugia, I-06100, Perugia, Italy

    E. Ballatori

Authors
  1. M. Tonato
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. F. Roila
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. A. Del Favero
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. E. Ballatori
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Tonato, M., Roila, F., Del Favero, A. et al. Antiemetics in cancer chemotherapy: historical perspective and current state of the art. Support Care Cancer 2, 150–160 (1994). https://doi.org/10.1007/BF00417473

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00417473

Key words

Search

Navigation